DOCSLIB.ORG

Investigations of the Role of Myomegalin in the Phosphorylation of Cardiac Myosin Binding Protein C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investigations of the Role of Myomegalin in the Phosphorylation of Cardiac Myosin Binding Protein C Investigations of the role of myomegalin in the phosphorylation of cardiac myosin binding protein C by Gerrida Mathilda Uys Dissertation presented for the degree of Doctor of Philosophy at the University of Stellenbosch Promoter: Prof. Johanna Catharina Moolman-Smook Faculty of Health Sciences Department of Biomedical Sciences December 2010 DECLARATION By submitting this thesis/dissertation electronically, I declare that the entirety of the work contained therein is my own, original work, and that I have not previously in its entirety or in part submitted it for obtaining any qualification. G.M. Uys December 2010 Copyright © 2010 University of Stellenbosch All rights reserved ABSTRACT Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac muscle disorder worldwide. The disease is characterized by extreme variability in the amount of hypertrophy that develops in different patients in response to sarcomeric protein-encoding gene mutations. The underlying defect in HCM is altered contractility of the sarcomere, primarily due to a defective sarcomere. Although numerous disease-causing genes have been identified for HCM, the factors that modify the amount of hypertrophy that develops in a given person are still unknown, it can be hypothesized that molecules that affect contractility can act as modifiers of the hypertrophic signal, and therefore influence the development of hypertrophy. Cardiac contractility is regulated by dynamic phosphorylation of proteins within the sarcomere by kinases such as cAMP-activated protein kinase A (PKA). Because speed and energy efficiency of cardiac muscle contraction has to be regulated in order to match the body’s needs, PKA is anchored close to its targets by A-kinase anchoring proteins (AKAPs) to enable spatio-temporal control of phosphorylation. Cardiac myosin binding protein-C (cMyBPC) and cardiac troponin I (cTNI) are HCM-causing sarcomeric proteins which regulate contractility in response to PKA phosphorylation. In a previous study, our laboratory identified a phosphodiesterase 4D-interacting protein as ligand of the N-terminal of cMyBPC via a yeast-two-hybrid (Y2H) cardiac library screen. This protein is also known in the literature as myomegalin (MMGL) isoform 4. Because phosphodiesterases and PKA are sometimes anchored by the same anchoring protein (AKAP), we hypothesized that MMGL isoform 4 acts as an AKAP by anchoring PKA to the phosphorylatable N-terminal of cMyBPC, and tested this by direct protein-protein interaction analyses in a yeast-based system. The MMGL cDNA was cloned into a bait vector, which was directly assessed for interaction with two distinct PKA regulatory-subunit preys. We further investigated the function of MMGL itself by using the Y2H bait to screen a cardiac cDNA library for novel MMGL interactors. All the prey clones identified via these Y2H analyses were subsequently sequenced to determine their identity. Based on their identities and subcellular localization, all putative Y2H MMGL-prey interactions were further assessed by additional, separate biochemical techniques viz. in vivo co-immunoprecipitation and in vivo 3D co-localization. The interactions between MMGL and its known PKA-phosphorylatable sarcomeric ligands were also investigated under conditions of β-adrenergic stress, by quantitatively measuring levels of co-localization before and upon addition of the β-adrenergic agonist isoproterenol. Furthermore, in order to evaluate the role of MMGL in cMyBPC phosphorylation, we assessed the expression of the different phosphorylation isoforms of cMyBPC, with and without β-adrenergic stimulation, in the context of siRNA-mediated MMGL knockdown. We further hypothesized that MMGL and PKA may serve as modifiers of the hypertrophic phenotype. This was tested by conducting a single nucleotide polymorphism (SNP) genotyping study of the genes encoding MMGL and the regulatory subunits of PKA viz. PDE4DIP, PRKAR1A and PRKAR2A, respectively, and comparing genotypic data with clinical phenotypic traits in a family-based association study. A panel of 353 individuals, including genetically and clinically affected as well as unaffected HCM individuals, was identified. All these individuals were screened for the presence or absence of all three South African HCM founder mutations, and blood was collected and DNA extracted. Genotypes at multiple SNPs in each gene were determined by subjecting the DNA samples to TaqMan® allelic discrimination technology. Statistical analysis using quantitative transmission disequilibrium testing (QTDT) was done in order to establish whether the difference in genotype in these three genes might have an effect on HCM phenotype. Our results showed that MMGL interacted with both PKA regulatory subunits as well as with other cardiac proteins that are PKA targets, including the sarcomeric protein cTNI. It was confirmed that two regulatory subunits of PKA (PRKAR1A and PRKAR2A), cardiac ankyrin repeat protein (CARP), copper metabolism gene MURR1 domain 4 (COMMD4), α-enolase (ENO1), β-enolase (ENO3) and cTNI are novel interactors of MMGL. In order to classify a protein as an AKAP, interaction with one of PKA’s regulatory subunits are prerequisite; MMGL showed interaction with both, confirming our hypothesis of MMGL being an AKAP, moreover, classifying it as a novel dual-specific sarcomeric AKAP. The identities of the AKAPs involved in the phosphorylation of cMyBPC and cTNI had been unknown; our results indicate that MMGL is the AKAP involved in the phosphorylation of both these PKA targets. We also showed that quantitatively more interaction occurs between MMGL and its sarcomeric ligands cMyBPC and cTNI under β-adrenergic stress. This implicates that under elevated cAMP levels, PKA is dynamically recruited by MMGL to the PKA targets cMyBPC and cTNI, presumably to mediate cardiac stress responses and leading to increased cardiac contractility. Furthermore, siRNA-mediated knockdown of MMGL lead to a reduction of cMyBPC levels under conditions of β-adrenergic stress, indicating that MMGL-assisted phosphorylation is requisite for protection of cMyBPC against proteolytic cleavage. The SNP modifier study indicated that one variant in PDE4DIP (rs1664005) showed strong association with numerous clinical hypertrophy traits, including maximal interventricular septum thickness, as well as a number of other composite score traits. Two variants in PRKAR1A (rs11651687 and rs3785906) also showed strong association with some of these clinical hypertrophy traits. These results therefore suggest that variants in these two genes may act as modifiers of the HCM phenotype. In conclusion, this study ascribes a novel function to MMGL isoform 4: it meets all criteria for classification as an AKAP and appears to be involved in the phosphorylation of cMyBPC as well as cTNI; hence MMGL is likely to be an important component in the regulation of cardiac contractility, and by extension, in the development of hypertrophy. This has further implications for understanding the patho-aetiology of mutations in cMyBPC and cTNI, and raises the question of whether MMGL might itself be considered a candidate HCM- causing factor. OPSOMMING Hipertrofiese kardiomiopatie (HKM) is die mees algemeenste oorerflike hartspier siekte wêreldwyd. Die siekte word gekenmerk deur die uiterste variasie in die hoeveelheid hipertrofie wat in verskillende pasiënte ontwikkel as gevolg van sarkomeriese proteïen-koderende mutasies. Die onderliggende gebrek in HKM is geaffekteerde kontraktiliteit van die sarkomeer, hoofsaaklik as gevolg van ‘n gebrekkige sarkomeer. Alhoewel daar verskeie siekte-veroorsakende gene vir HKM geïdentifiseer is, bly die faktore wat die hoeveelheid hipertrofie in ‘n gegewe persoon modifiseer, onbekend. Daar kan dus gehipotiseer word dat molekules wat kontraktiliteit beïnvloed as modifiseerders van die hipertrofiese sein kan optree, en dus die ontwikkeling van hipertrofie beïnvloed. Hartspier kontraktiliteit word gereguleer deur die dinamiese fosforilasie van proteïene binne die sarkomeer deur kinases soos bv. cAMP-geaktiveerde proteïen kinase A (PKA). Die spoed en energie doeltreffendheid van hartspier kontraksie moet gereguleer word om by die liggaam se behoeftes aan te pas; dus word PKA naby sy teikens deur A-kinase anker proteïene (AKAPs) geanker om sodoende die beheer van fosforilasie beide in die korrekte area sowel as tydsduur te reguleer. Kardiale miosien-bindingsproteïen C (cMyBPC), asook kardiale troponien I (cTNI), is beide HKM-veroorsakende sarkomeriese proteïene wat kontraktiliteit beheer deur middel van fosforilasie deur PKA. In ‘n vorige studie in ons laboratorium is ‘n fosfodiesterase 4D-interaksie proteïen as bindingsgenoot van die N-terminaal van cMyBPC geïdentifiseer deur middel van ‘n gis-twee-hibried (G2H) kardiale biblioteek sifting. In die literatuur staan dié proteïen ook bekend as miomegalin (MMGL) isovorm 4. Fosfodiesterases en PKA word soms deur dieselfde anker proteïen (AKAP) geanker, dus het ons hipotiseer dat MMGL isovorm 4 ook as AKAP kan optree deur PKA aan die fosforileerbare N-terminaal van cMyBPC te anker. Die hipotese is getoets deur middel van direkte proteïen-proteïen interaksie analises in ‘n gis-gebaseerde sisteem. Die MMGL cDNA was in ‘n jag-plasmied gekloneer, wat toe direk ge-evalueer is vir interaksie met twee verskillende PKA regulatoriese-subeenheid prooi-plasmiede. Die funksie van MMGL self is verder ondersoek deur die G2H jag-plasmied te gebruik om ‘n kardiale cDNA biblioteek te sif, sodoende om nuwe MMGL bindingsgenote
Load more

Recommended publications
  • Open Full Page
    Research Article Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization Go¨ran Jo¨nsson,1 Tara L. Naylor,5 Johan Vallon-Christersson,1 Johan Staaf,1 Jia Huang,5 M. Renee Ward,5 Joel D. Greshock,5 Lena Luts,4 Ha˚kan Olsson,1 Nazneen Rahman,6 Michael Stratton,6 Markus Ringne´r,3 A˚ke Borg,1,2 and Barbara L. Weber5 1Department of Oncology, University Hospital; 2Lund Strategic Research Center for Stem Cell Biology and Cell Therapy and 3Department of Theoretical Physics, Lund University; and 4Department of Pathology, University Hospital, Lund, Sweden; 5Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania; and 6Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom Abstract of additional predisposing genes, although technical limitations Mutations in BRCA1 and BRCA2 account for a significant and the complexity of BRCA gene regulation and mutation proportion of hereditary breast cancers. Earlier studies have spectrum can probably explain why some disease-causing muta- shown that inherited and sporadic tumors progress along tions are missed (2). BRCA1 and BRCA2 function as classic tumor different somatic genetic pathways and that global gene suppressor genes with frequent loss of the wild-type allele in expression profiles distinguish between these groups. To tumors of mutation carriers. The BRCA1 protein has been determine whether genomic profiles similarly discriminate implicated in a broad range of cellular functions, including repair among BRCA1, BRCA2, and sporadic tumors, we established of double-strand breaks by homologous recombination, cell cycle DNA copy number profiles using comparative genomic checkpoint control, chromatin remodeling, and transcriptional hybridization to BAC-clone microarrays providing <1 Mb regulation.
    [Show full text]
  • Polyclonal Antibody to PDE4D - Aff - Purified
    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AP06558PU-N Polyclonal Antibody to PDE4D - Aff - Purified Alternate names: 5'-cyclic phosphodiesterase 4D, DPDE3, DPDE3, EC=3.1.4.17, PDE43, PDE4D, cAMP- specific 3' Quantity: 0.1 mg Concentration: 1.0 mg/ml Background: Phosphodiesterases (PDE) hydrolyze cAMP to 5’AMP and thus play a critical role in the regulation of intracellular cAMP. Division of the PDE superfamily by sequence homology and enzymatic properties yields 11 PDE families. A unique upstream conserved region (UCR) characterizes the PDE4 family. Four separate genes (A-D) encode the PDE4 enzymes, and alternative splicing generates short or long isoforms of each gene. Long PDE4 isoforms contain both UCR1 and UCR2 while short PDE4 isoforms possess only UCR2. Both UCR domains are necessary for dimerization of PDE4 isoforms. The human PDE4D gene maps to chromosome 5q12. The splice variants include isoforms PDE4D1-6. Uniprot ID: Q08499 NCBI: NP_001098101.1 GeneID: 5144 Host: Rabbit Immunogen: Synthetic peptide, corresponding to amino acids 30-70 Human PDE4D. Format: State: Liquid purified Ig fraction Purification: Affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) Buffer System: Phosphate buffered saline (PBS), pH 7.2. Preservatives: 15 mM sodium azide Applications: Western blot: 1/500-1/1000. Immunohistochemistry on paraffin sections: 1/50-1/200.
    [Show full text]
  • Changing the Name of the NBPF/DUF1220 Domain to the Olduvai Domain [Version 2; Peer Review: 3 Approved]
    F1000Research 2018, 6:2185 Last updated: 31 AUG 2021 OPINION ARTICLE Changing the name of the NBPF/DUF1220 domain to the Olduvai domain [version 2; peer review: 3 approved] Previously titled: A proposal to change the name of the NBPF/DUF1220 domain to the Olduvai domain James M. Sikela 1, Frans van Roy2,3 1Department of Biochemistry and Molecular Genetics, Human Medical Genetics and Neuroscience Programs, University of Colorado School of Medicine, Aurora, CO, 80045, USA 2Department of Biomedical Molecular Biology, Ghent University, Ghent, 9052, Belgium 3VIB-UGent Center for Inflammation Research, Ghent, 9052, Belgium v2 First published: 28 Dec 2017, 6:2185 Open Peer Review https://doi.org/10.12688/f1000research.13586.1 Latest published: 17 Jul 2018, 6:2185 https://doi.org/10.12688/f1000research.13586.2 Reviewer Status Invited Reviewers Abstract We are jointly proposing a new name for a protein domain of 1 2 3 approximately 65 amino acids that has been previously termed NBPF or DUF1220. Our two labs independently reported the initial studies of version 2 this domain, which is encoded almost entirely within a single gene (revision) report report family. The name Neuroblastoma Breakpoint Family (NBPF) was 17 Jul 2018 applied to this gene family when the first identified member of the family was found to be interrupted in an individual with version 1 neuroblastoma. 28 Dec 2017 report report report Prior to this discovery, the Pfam database had termed the domain DUF1220, denoting it as one of many protein domains of unknown f unction. It has been Pfam’s intention to use “DUF” nomenclature to 1.
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • A Newly Identified Myomegalin Isoform Functions in Golgi Microtubule Organization and ER–Golgi Transport
    ß 2014. Published by The Company of Biologists Ltd | Journal of Cell Science (2014) 127, 4904–4917 doi:10.1242/jcs.155408 RESEARCH ARTICLE A newly identified myomegalin isoform functions in Golgi microtubule organization and ER–Golgi transport Zhe Wang, Chao Zhang and Robert Z. Qi* ABSTRACT the formation of ER–Golgi cargo carriers that associate with dynein–dynactin to move along microtubules towards the Golgi The Golgi of mammalian cells is known to be a major microtubule- (Presley et al., 1997; Scales et al., 1997; Watson et al., 2005). organizing site that requires microtubules for its organization and The Golgi serves as a major microtubule-organizing center protein trafficking. However, the mechanisms underlying the (Chabin-Brion et al., 2001; Efimov et al., 2007; Miller et al., 2009; microtubule organization of the Golgi remain obscure. We used Rivero et al., 2009). For example, almost half of all cellular immunoprecipitation coupled with mass spectrometry to identify a microtubules originate from the Golgi in human retinal pigment widely expressed isoform of the poorly characterized muscle protein epithelial RPE1 cells (Efimov et al., 2007). Moreover, microtubule myomegalin. This newly identified isoform, myomegalin variant 8 nucleation at the Golgi does not require centrosomes, and it (MMG8), localized predominantly to cis-Golgi networks by interacting depends instead on c-tubulin (Efimov et al., 2007), the principal with AKAP450 (also known as AKAP9), and this interaction with microtubule nucleator in cells, which exists in the form of c-tubulin AKAP450 was required for the stability of both proteins. Disrupting complexes (cTuCs). The cis-Golgi proteins AKAP450 (also known MMG8 expression affected endoplasmic reticulum (ER)-to-Golgi as AKAP9, AKAP350, CG-NAP and hyperion) and GMAP210 trafficking and caused Golgi fragmentation.
    [Show full text]
  • Supplementary Data
    Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type
    [Show full text]
  • Downloaded 18 July 2014 with a 1% False Discovery Rate (FDR)
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer Permalink https://escholarship.org/uc/item/0t47b9ws Author Spiciarich, David Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Chemistry in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Professor Matthew B. Francis Professor Amy E. Herr Fall 2017 Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer © 2017 by David Spiciarich Abstract Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich Doctor of Philosophy in Chemistry University of California, Berkeley Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Changes in glycosylation have long been appreciated to be part of the cancer phenotype; sialylated glycans are found at elevated levels on many types of cancer and have been implicated in disease progression. However, the specific glycoproteins that contribute to cell surface sialylation are not well characterized, specifically in bona fide human cancer. Metabolic and bioorthogonal labeling methods have previously enabled enrichment and identification of sialoglycoproteins from cultured cells and model organisms. The goal of this work was to develop technologies that can be used for detecting changes in glycoproteins in clinical models of human cancer.
    [Show full text]
  • CDK5RAP2 Functions in Centrosome to Spindle Pole Attachment and DNA Damage Response
    JCB: Article CDK5RAP2 functions in centrosome to spindle pole attachment and DNA damage response Alexis R. Barr,1,2 John V. Kilmartin,3 and Fanni Gergely1,2 1Cancer Research UK Cambridge Research Institute, Cambridge CB2 0RE, England, UK 2Department of Oncology, University of Cambridge, Cambridge CB2 3RA, England, UK 3Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, England, UK he centrosomal protein, CDK5RAP2, is mutated fail to recruit specific PCM components that mediate in primary microcephaly, a neurodevelopmental attachment to spindle poles. Furthermore, we show that Tdisorder characterized by reduced brain size. The the CNN1 domain enforces cohesion between parental Drosophila melanogaster homologue of CDK5RAP2, centrioles during interphase and promotes efficient DNA centrosomin (Cnn), maintains the pericentriolar matrix damage–induced G2 cell cycle arrest. Because mitotic (PCM) around centrioles during mitosis. In this study, we spindle positioning, asymmetric centrosome inheritance, demonstrate a similar role for CDK5RAP2 in vertebrate and DNA damage signaling have all been implicated cells. By disrupting two evolutionarily conserved domains in cell fate determination during neurogenesis, our find- of CDK5RAP2, CNN1 and CNN2, in the avian B cell line ings provide novel insight into how impaired CDK5RAP2 DT40, we find that both domains are essential for link- function could cause premature depletion of neural stem ing centrosomes to mitotic spindle poles. Although struc- cells and thereby microcephaly. turally intact, centrosomes lacking the CNN1 domain Introduction The centrosome consists of a pair of centrioles surrounded by 1995; Merdes et al., 1996, 2000; Gordon et al., 2001; Quintyne the pericentriolar matrix (PCM). In most animal cells, it is the and Schroer, 2002; Silk et al., 2009).
    [Show full text]
  • And an Imatinib-Responsive Myeloproliferative Disorder1
    [CANCER RESEARCH 64, 2673–2676, April 15, 2004] Advances in Brief NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder1 Jose´L. Vizmanos,1 Francisco J. Novo,1 Jose´P. Roma´n,1 E. Joanna Baxter,2 Idoya Lahortiga,1 Marı´a J. Larra´yoz,1 Marı´a D. Odero,1 Pilar Giraldo,3 Marı´a J. Calasanz,1 and Nicholas C. P. Cross2 1Department of Genetics, University of Navarra, Pamplona, Spain; 2Wessex Regional Genetics Laboratory, Salisbury and Human Genetics Division, University of Southampton, Southampton, United Kingdom; and 3Haematology Service, Miguel Servet Hospital, Zaragoza, Spain Abstract mesylate (4–7) although this drug is inactive against FGFR1 fusions (8). Consequently, identification of patients with PDGFRB rearrange- We describe a new PDGFRB fusion associated with a t(5;14)(q33;q24) ments is very important for their clinical management. Rearrangement in a patient with a longstanding chronic myeloproliferative disorder with of PDGFRB was first described in patients with the t(5;12)(q31;p12), eosinophilia. After confirmation of PDGFRB involvement and definition of the chromosome 14 breakpoint by fluorescence in situ hybridization, leading to the formation of the ETV6-PDGFRB fusion (9). Subse- candidate partner genes were selected on the basis of the presence of quently, PDGFRB has been found fused to CEV14/TRIP11 by the predicted oligomerization domains believed to be an essential feature of t(5;14)(q31;p12) (Ref. 10); HIP1 by the t(5;7)(q33;q11.2) (Ref.
    [Show full text]
  • DUF1220-Domain Copy Number Implicated in Human Brain-Size Pathology and Evolution
    ARTICLE DUF1220-Domain Copy Number Implicated in Human Brain-Size Pathology and Evolution Laura J. Dumas,1 Majesta S. O’Bleness,1 Jonathan M. Davis,1,2 C. Michael Dickens,1 Nathan Anderson,1 J.G. Keeney,1 Jay Jackson,1 Megan Sikela,1 Armin Raznahan,3 Jay Giedd,3 Judith Rapoport,3 Sandesh S.C. Nagamani,4 Ayelet Erez,4 Nicola Brunetti-Pierri,5,6 Rachel Sugalski,7 James R. Lupski,4 Tasha Fingerlin,2 Sau Wai Cheung,4 and James M. Sikela1,* DUF1220 domains show the largest human-lineage-specific increase in copy number of any protein-coding region in the human genome and map primarily to 1q21, where deletions and reciprocal duplications have been associated with microcephaly and macro- cephaly, respectively. Given these findings and the high correlation between DUF1220 copy number and brain size across primate line- À ages (R2 ¼ 0.98; p ¼ 1.8 3 10 6), DUF1220 sequences represent plausible candidates for underlying 1q21-associated brain-size pathol- ogies. To investigate this possibility, we used specialized bioinformatics tools developed for scoring highly duplicated DUF1220 sequences to implement targeted 1q21 array comparative genomic hybridization on individuals (n ¼ 42) with 1q21-associated micro- cephaly and macrocephaly. We show that of all the 1q21 genes examined (n ¼ 53), DUF1220 copy number shows the strongest asso- ciation with brain size among individuals with 1q21-associated microcephaly, particularly with respect to the three evolutionarily conserved DUF1220 clades CON1(p ¼ 0.0079), CON2 (p ¼ 0.0134), and CON3 (p ¼ 0.0116). Interestingly, all 1q21 DUF1220-encoding genes belonging to the NBPF family show significant correlations with frontal-occipital-circumference Z scores in the deletion group.
    [Show full text]
  • An Expanded Proteome of Cardiac T-Tubules☆
    Cardiovascular Pathology 42 (2019) 15–20 Contents lists available at ScienceDirect Cardiovascular Pathology Original Article An expanded proteome of cardiac t-tubules☆ Jenice X. Cheah, Tim O. Nieuwenhuis, Marc K. Halushka ⁎ Department of Pathology, Division of Cardiovascular Pathology, Johns Hopkins University SOM, Baltimore, MD, USA article info abstract Article history: Background: Transverse tubules (t-tubules) are important structural elements, derived from sarcolemma, found Received 27 February 2019 on all striated myocytes. These specialized organelles create a scaffold for many proteins crucial to the effective Received in revised form 29 April 2019 propagation of signal in cardiac excitation–contraction coupling. The full protein composition of this region is un- Accepted 17 May 2019 known. Methods: We characterized the t-tubule subproteome using 52,033 immunohistochemical images covering Keywords: 13,203 proteins from the Human Protein Atlas (HPA) cardiac tissue microarrays. We used HPASubC, a suite of Py- T-tubule fi Proteomics thon tools, to rapidly review and classify each image for a speci c t-tubule staining pattern. The tools Gene Cards, Caveolin String 11, and Gene Ontology Consortium as well as literature searches were used to understand pathways and relationships between the proteins. Results: There were 96 likely t-tubule proteins identified by HPASubC. Of these, 12 were matrisome proteins and 3 were mitochondrial proteins. A separate literature search identified 50 known t-tubule proteins. A comparison of the 2 lists revealed only 17 proteins in common, including 8 of the matrisome proteins. String11 revealed that 94 of 127 combined t-tubule proteins generated a single interconnected network. Conclusion: Using HPASubC and the HPA, we identified 78 novel, putative t-tubule proteins and validated 17 within the literature.
    [Show full text]
  • Exome Sequencing Identifies PDE4D Mutations As Another Cause of Acrodysostosis
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector REPORT Exome Sequencing Identifies PDE4D Mutations as Another Cause of Acrodysostosis Caroline Michot,1,10 Carine Le Goff,1,10 Alice Goldenberg,2 Avinash Abhyankar,3 Ce´line Klein,1 Esther Kinning,4 Anne-Marie Guerrot,2 Philippe Flahaut,5 Alice Duncombe,6 Genevieve Baujat,1 Stanislas Lyonnet,1 Caroline Thalassinos,7 Patrick Nitschke,8 Jean-Laurent Casanova,3,9 Martine Le Merrer,1 Arnold Munnich,1 and Vale´rie Cormier-Daire1,* Acrodysostosis is a rare autosomal-dominant condition characterized by facial dysostosis, severe brachydactyly with cone-shaped epiph- yses, and short stature. Moderate intellectual disability and resistance to multiple hormones might also be present. Recently, a recurrent mutation (c.1102C>T [p.Arg368*]) in PRKAR1A has been identified in three individuals with acrodysostosis and resistance to multiple hormones. After studying ten unrelated acrodysostosis cases, we report here de novo PRKAR1A mutations in five out of the ten individ- uals (we found c.1102C>T [p.Arg368*] in four of the ten and c.1117T>C [p.Tyr373His] in one of the ten). We performed exome sequencing in two of the five remaining individuals and selected phosphodiesterase 4D (PDE4D) as a candidate gene. PDE4D encodes a class IV cyclic AMP (cAMP)-specific phosphodiesterase that regulates cAMP concentration. Exome analysis detected heterozygous PDE4D mutations (c.673C>A [p.Pro225Thr] and c.677T>C [p.Phe226Ser]) in these two individuals. Screening of PDE4D identified heterozygous mutations (c.568T>G [p.Ser190Ala] and c.1759A>C [p.Thr587Pro]) in two additional acrodysostosis cases.
    [Show full text]